Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.
作者信息
Franco Laura, Becattini Cecilia, Vanni Simone, Sbrojavacca Rodolfo, Nitti Cinzia, Manina Giorgia, Masotti Luca, Pomero Fulvio, Cattinelli Sergio, Cappelli Roberto, Re Roberta, Agnelli Giancarlo
机构信息
Vascular Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy.
Department of Emergency Medicine, "Careggi" University Hospital, Florence, Italy.
出版信息
Blood Transfus. 2018 Jul;16(4):387-391. doi: 10.2450/2017.0335-16. Epub 2017 Mar 15.
Abstract
摘要
相似文献
1
Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.
Blood Transfus. 2018 Jul;16(4):387-391. doi: 10.2450/2017.0335-16. Epub 2017 Mar 15.
2
Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study.
Int J Cardiol. 2018 Aug 15;265:103-107. doi: 10.1016/j.ijcard.2018.04.117. Epub 2018 Apr 25.
3
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28-36. doi: 10.1093/ehjcvp/pvw031. Epub 2016 Sep 27.
4
Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making.
Int J Cardiol. 2017 Oct 15;245:174-177. doi: 10.1016/j.ijcard.2017.07.043. Epub 2017 Jul 14.
5
Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation.
J Thromb Thrombolysis. 2016 Nov;42(4):573-8. doi: 10.1007/s11239-016-1410-z.
6
Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
Am J Cardiol. 2017 May 15;119(10):1590-1595. doi: 10.1016/j.amjcard.2017.02.015. Epub 2017 Mar 28.
7
Assessment of risk factors for bleeding in Japanese patients with non-valvular atrial fibrillation receiving warfarin treatment: A subanalysis of the J-RHYTHM Registry.
Int J Cardiol. 2015 Dec 15;201:308-10. doi: 10.1016/j.ijcard.2015.08.059. Epub 2015 Aug 5.
8
The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
J Stroke Cerebrovasc Dis. 2018 Nov;27(11):3280-3288. doi: 10.1016/j.jstrokecerebrovasdis.2018.07.028. Epub 2018 Aug 16.
9
Bleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis.
J Interv Card Electrophysiol. 2015 Nov;44(2):105-11. doi: 10.1007/s10840-015-0053-x. Epub 2015 Sep 5.
10
Comparison of Bleeding Risk Scores in Patients With Nonvalvular Atrial Fibrillation Starting Direct Oral Anticoagulants.
Rev Esp Cardiol (Engl Ed). 2017 Oct;70(10):878-880. doi: 10.1016/j.rec.2017.01.021. Epub 2017 Feb 24.
引用本文的文献
1
Once- versus twice-daily direct oral anticoagulants after ischemic stroke in atrial fibrillation - A post-hoc analysis of the ELAN trial.
Eur Stroke J. 2025 Aug 11:23969873251360974. doi: 10.1177/23969873251360974.
2
Frailty and Atrial Fibrillation: A Closer Look at the FRAIL-AF Trial.
Arq Bras Cardiol. 2024 Jun 17;121(5):e20230671. doi: 10.36660/abc.20230671. eCollection 2024.
3
Qualitative experiences, values, and decisional needs of patients with unprovoked venous thromboembolism who suffer bleeding-"This pill will keep you alive tonight".
Res Pract Thromb Haemost. 2024 Mar 1;8(2):102360. doi: 10.1016/j.rpth.2024.102360. eCollection 2024 Feb.
4
Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry.
J Thromb Thrombolysis. 2024 Apr;57(4):710-720. doi: 10.1007/s11239-024-02957-4. Epub 2024 Mar 16.
5
Balancing risks of recurrent venous thromboembolism and bleeding with extended anticoagulation: a decision analysis.
Res Pract Thromb Haemost. 2023 Nov 26;8(1):102274. doi: 10.1016/j.rpth.2023.102274. eCollection 2024 Jan.
6
Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism.
Blood Adv. 2023 Jan 24;7(2):205-213. doi: 10.1182/bloodadvances.2022007263.
7
Serial use of existing clinical decisions aids can reduce computed tomography pulmonary angiography for pulmonary embolism.
Intern Emerg Med. 2021 Nov;16(8):2251-2259. doi: 10.1007/s11739-021-02703-1. Epub 2021 Mar 20.
8
Impact of pharmacist-conducted anticoagulation patient education and telephone follow-up on transitions of care: a randomized controlled trial.
BMC Health Serv Res. 2021 Feb 16;21(1):151. doi: 10.1186/s12913-021-06156-2.
9
A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants.
J Clin Med. 2020 Sep 15;9(9):2984. doi: 10.3390/jcm9092984.
10
Thirty-day mortality in atrial fibrillation patients with gastrointestinal bleeding in the emergency department: differences between direct oral anticoagulant and warfarin users.
Intern Emerg Med. 2020 Mar;15(2):311-318. doi: 10.1007/s11739-019-02229-7. Epub 2019 Nov 21.
本文引用的文献
1
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
Thromb Haemost. 2016 Nov 30;116(6):1159-1164. doi: 10.1160/TH16-02-0137. Epub 2016 Sep 1.
2
Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials.
Int J Cardiol. 2016 Sep 1;218:235-239. doi: 10.1016/j.ijcard.2016.05.059. Epub 2016 May 14.
3
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.
J Thromb Haemost. 2015 Nov;13(11):2119-26. doi: 10.1111/jth.13140.
4
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
Eur Heart J. 2016 Apr 7;37(14):1145-53. doi: 10.1093/eurheartj/ehv466. Epub 2015 Sep 1.
5
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.
Blood. 2014 Aug 7;124(6):955-62. doi: 10.1182/blood-2014-03-563577. Epub 2014 May 23.
6
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
J Thromb Haemost. 2014;12(3):320-8. doi: 10.1111/jth.12485.
7
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
8
Edoxaban versus warfarin in patients with atrial fibrillation.
N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.
9
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31.
10
Oral apixaban for the treatment of acute venous thromboembolism.
N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.
Zotero 插件